Results 81 to 90 of about 17,963 (297)
Aggressive and Malignant Prolactinomas [PDF]
Neuroendocrinology, 2019 Prolactin-secreting tumors (prolactinomas) represent the most common pituitary tumor type, accounting for 47–66% of functional pituitary tumors. Prolactinomas are usually benign and controllable tumors as they express abundant levels of dopamine type 2 receptor (D2), and can be treated with dopaminergic drugs, effectively reducing prolactin levels and ...
Eyrc +8 more
openaire +7 more sources
Management of prolactinoma during pregnancy and postpartum
Journal of Integrated Health Sciences, 2015 Prolactinoma is classified as microprolactinoma when it measures
Om J Lakhani +3 more
doaj +1 more source
Hypersomatotropism and Hypercortisolism Caused by a Plurihormonal Pituitary Adenoma in a Dog
Journal of Veterinary Internal Medicine, Volume 39, Issue 4, July/August 2025.ABSTRACT A 12‐year‐old, male Labrador Retriever was presented because of polyuria, polydipsia, polyphagia, joint pain, and physical features consistent with acromegaly. Circulating insulin‐like growth factor‐1 (IGF‐1) concentration was increased (> 1000 ng/mL; reference interval [RI], 42–449), suggestive of hypersomatotropism.
Elber A. Soler Arias +3 more
wiley +1 more source
Treatment-resistant pediatric giant prolactinoma and multiple endocrine neoplasia type 1 [PDF]
, 2015 Background Pediatric pituitary adenomas are rare, accounting for A) being eventually identified in intron 4 of the MEN1 gene, potentially explaining the difficulties in management of this tumor.
Bulwer, C +5 more
core +1 more source
Brain and Behavior, Volume 15, Issue 6, June 2025.Surveying 300 neurologists, psychiatrists, and family physicians, this study demonstrates discipline‐specific strengths‐imaging (neurology), diagnosis (psychiatry), and pharmacological follow‐up (family medicine)‐yet persistent gaps in holistic care of late‐onset bipolar disorder in elders.
Yagmur Sever Fidan +6 more
wiley +1 more source
Anti-EGFL7 antibodies inhibit rat prolactinoma MMQ cells proliferation and PRL secretion
Open Chemistry, 2018 Prolactinoma is the most frequently diagnosed pituitary tumors. Dopamine agonists (DAs) are recognized as first-line therapy; however, approximately 10% patients will develop resistance to DAs therapy.
Liu Qian +5 more
doaj +1 more source
An uncommon cause of osteoporosis
Journal of Family Medicine and Primary Care, 2018 Osteoporosis in the younger age group is an important cause of morbidity. Prolactinoma is an uncommon but reversible cause of osteoporosis. The main mechanisms of osteoporosis in prolactinoma are reduced osteoblast activity and hypogonadism. A high index
Rohit Barnabas +5 more
doaj +1 more source
SAGE Open Medical Case Reports, 2023 Hypogonadotropic hypogonadism is a common finding in patients who are diagnosed with a prolactinoma. It can be accompanied by the presence of other pituitary hormone deficits, including secondary adrenal insufficiency and central hypothyroidism.
Lakshmi P Menon, Dinesh Edem
doaj +1 more source
Psychiatry and Clinical Neurosciences Reports, Volume 4, Issue 2, June 2025.Abstract Background Impulse control disorders (ICDs), including hypersexuality, are associated with adverse effects of dopamine agonists, such as pramipexole, particularly in the treatment of Parkinson's disease and restless legs syndrome (RLS). The underlying mechanisms remain unclear in ICDs in patients with RLS, and no neuroimaging studies have ...
Toshiki Obata +7 more
wiley +1 more source
Pathogenesis, diagnosis and current treatment of prolactinoma: a review of the literature
Quality in Sport: Prolactinoma is a benign tumor of the pituitary gland that leads to the overproduction of prolactin. It is the most common type of pituitary adenoma, accounting for approximately 50% of all pituitary tumors. The clinical presentation of prolactinoma
Monika Szyszka +6 more
doaj +1 more source